Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	4	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	5	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	6	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	7	AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS	8	AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS	9	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS	10	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	11	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS	12	SEP 27	STANDARDS will no longer be available on STN
NEWS	13	SEP 27	SWETSCAN will no longer be available on STN

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:15:35 ON 20 OCT 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:15:50 ON 20 OCT 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 OCT 2004 HIGHEST RN 765878-56-6
DICTIONARY FILE UPDATES: 19 OCT 2004 HIGHEST RN 765878-56-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

```
=> e bicalutamide/cn
E1            1     BICALON/CN
E2            1     BICALPHOS/CN
E3            1 --> BICALUTAMIDE/CN
E4            1     BICARBAMALDEHYDE/CN
E5            1     BICARBAMAMIC ACID/CN
E6            1     BICARBAMAMIDE/CN
E7            1     BICARBAMAMIDE, 2-(4-BIPHENYLYL)-N-METHYL-3-PHENYL-/CN
E8            1     BICARBAMAMIDINE/CN
E9            1     BICARBAMIC ACID/CN
E10           1     BICARBAMIC ACID (4-AMINO-3,5-XYLYL)-, DIETHYL ESTER/CN
E11           1     BICARBAMIC ACID, (((1-CARBOXY-2-HYDROXYETHYL)CARBAMOYL)METHY
                    L)-, 1,4-DIBENZYL METHYL ESTER/CN
E12           1     BICARBAMIC ACID, (((CARBOXYMETHYL)CARBAMOYL)METHYL)-, DIBENZ
                    YL METHYL ESTER/CN

=> s e3
L1            1 BICALUTAMIDE/CN

=> d scan

L1    1 ANSWERS   REGISTRY  COPYRIGHT 2004 ACS on STN
IN    Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-
      fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- (9CI)
MF    C18 H14 F4 N2 O4 S
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     5.27       5.48

FILE 'CAPLUS' ENTERED AT 18:16:58 ON 20 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 20 Oct 2004  VOL 141 ISS 17
FILE LAST UPDATED: 19 Oct 2004  (20041019/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l1
L2          402 L1

=> s l2 and micro?
       2105390 MICRO?
L3           48 L2 AND MICRO?

=> s l3 and particle
         621330 PARTICLE
         701149 PARTICLES
        1052058 PARTICLE
                  (PARTICLE OR PARTICLES)
L4            5 L3 AND PARTICLE

=> s l3 and diameter
          20680 DIAMETER
           1897 DIAMETERS
          22274 DIAMETER
                  (DIAMETER OR DIAMETERS)
         381322 DIAM
          40439 DIAMS
         408143 DIAM
                  (DIAM OR DIAMS)
         422933 DIAMETER
                  (DIAMETER OR DIAM)
L5            0 L3 AND DIAMETER

=> s l2 and micronized
           2954 MICRONIZED
```

L6 2 L2 AND MICRONIZED

=> dup rem l6 l4
PROCESSING COMPLETED FOR L6
PROCESSING COMPLETED FOR L4
L7 5 DUP REM L6 L4 (2 DUPLICATES REMOVED)

=> d l7 ibib hitstr abs 1-5

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2004:182593 CAPLUS
DOCUMENT NUMBER: 140:235504
TITLE: Preparation and crystallization of bicalutamide
INVENTOR(S): Dolitzky, Ben-Zion; Reany, Ofer; Shammai, Jenny
PATENT ASSIGNEE(S): Israel
SOURCE: U.S. Pat. Appl. Publ., 12 pp., Cont.-in-part of U.S. Ser. No. 170,721.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004044249	A1	20040304	US 2003-606403		20030625
US 2003045741	A1	20030306	US 2002-170721		20020613
US 6737550	B2	20040518			
US 2004059147	A1	20040325	US 2003-668982		20030922
US 6797843	B2	20040928			
US 2004167349	A1	20040826	US 2004-791468		20040301
US 2004176633	A1	20040909	US 2004-796313		20040308
US 2004176638	A1	20040909	US 2004-796822		20040308
PRIORITY APPLN. INFO.:			US 2001-298009P	P	20010613
			US 2002-371069P	P	20020409
			US 2002-170721	A2	20020613

OTHER SOURCE(S): CASREACT 140:235504
IT **90357-06-5P**, Bicalutamide
RL: PEP (Physical, engineering or chemical process); PUR (Purification or recovery); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(preparation, micronization and crystallization of bicalutamide)
RN 90357-06-5 CAPLUS
CN Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



AB Racemic N-[4-cyano-3-trifluoromethylphenyl]-3-[4-fluorophenylsulfonyl]-2-hydroxy-2-methylpropionamide (bicalutamide) was prepared starting from Et pyruvate and Me methacrylate. Thus, 5-amino-2-cyanobenzotrifluoride was treated with DABCO and reacted with deprotonated Et 2-(4-

fluorophenylsulfonyl)-2-hydroxy-2-methylpropionate (prepared from Et pyruvate) to give 40% bicalutamide. **Micronized** particles of bicalutamide can be obtained as pharmaceutical compns. that are useful for its anti-androgen activity (no data). Bicalutamide intermediates were also prepared, including Et 2-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropionate, Me 2,3-epoxy-2-methylpropionate and 2-hydroxy-2-methyl-3-(4-fluorophenylthio)propionic acid. The present invention further discloses the isolation and purification of bicalutamide by various crystallization methods.

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:472643 CAPLUS
DOCUMENT NUMBER: 139:30801
TITLE: Assays and implements for determining and modulating heat shock protein 90 (HSP90) binding activity, and therapeutic use
INVENTOR(S): Kamal, Adeela; Burrows, Francis J.; Zhang, Lin; Boehm, Marcus F.
PATENT ASSIGNEE(S): Conforma Therapeutics Corporation, USA
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003050295	A2	20030619	WO 2002-US39993	20021212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003066005	A2	20030814	WO 2003-US4283	20030210
WO 2003066005	A3	20040610		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004054624	A1	20040701	WO 2003-US18776	20030612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,				

CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-340762P P 20011212
US 2002-355275P P 20020208
US 2002-367055P P 20020322
WO 2002-US39993 A 20021212

OTHER SOURCE(S): CASREACT 139:30801

IT **90357-06-5**, Bicalutamide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(assays and implements for determining and modulating heat shock protein 90 binding activity, and therapeutic use with other agents)

RN 90357-06-5 CAPLUS

CN Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



AB Ligand binding assays as applied to HSP90s as receptors or ligands, and reagents useful therefore, are described and claimed, as are methods of assaying for HSP90 modulators and methods of using the resulting products identified thereby. The methodol. of the invention may be used in the treatment and prevention of an HSP90-mediated disease, e.g. cancer. Modulators of the invention include e.g. ansamycins.

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2002:964133 CAPLUS
DOCUMENT NUMBER: 138:24551
TITLE: Preparation of rac-bicalutamide
INVENTOR(S): Dolitzky, Ben-Zion; Reany, Ofer; Shamai, Jenny
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.; Biogal Gyogyszergyar
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100339	A2	20021219	WO 2002-US18329	20020613
WO 2002100339	A3	20031016		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1406855 A2 20040414 EP 2002-739801 20020613

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2001-298009P P 20010613

US 2002-371069P P 20020409

WO 2002-US18329 W 20020613

priority docs.

OTHER SOURCE(S): CASREACT 138:24551

IT **90357-06-5P**, Bicalutamide

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of rac-bicalutamide)

RN 90357-06-5 CAPLUS

CN Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



AB Racemic and optically active N-[4-cyano-3-trifluoromethylphenyl]-3-[4-fluorophenylsulfonyl]-2-hydroxy-2-Me propionamide (bicalutamide) were prepared starting from Et pyruvate and Me methacrylate. Thus, 5-amino-2-cyanobenzotrifluoride was treated with DABCO and reacted with deprotonated ethyl-[2-(4-fluorophenyl sulfone)]-2-hydroxy propionate (prepared from Et pyruvate) to give %40 rac-bicalutamide. **Micronized** particles of rac-bicalutamide can be obtained as pharmaceutical compns. that are useful for its anti-androgen activity (no data). Bicalutamide intermediates were also prepared, including ethyl-[2-(4-fluorophenyl sulfone)]-2-hydroxy propionate, 1,2-epoxy-2-Me propionate and 2-hydroxy-2-methyl-3-(4-fluorophenylthio) propionic acid.

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:637506 CAPLUS

DOCUMENT NUMBER: 137:190729

TITLE: Novel modified-release formulation containing amphiphilic lipids as a hydrophobic matrix former

INVENTOR(S): Juppo, Anne

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.

SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064121	A1	20020822	WO 2002-SE228	20020208

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1368006	A1	20031210	EP 2002-710645		20020208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2002006825	A	20040225	BR 2002-6825		20020208
JP 2004518709	T2	20040624	JP 2002-563916		20020208
US 2004067256	A1	20040408	US 2003-467900		20030811
NO 2003003564	A	20031002	NO 2003-3564		20030812
PRIORITY APPLN. INFO.:			SE 2001-477	A	20010213
			SE 2001-478	A	20010213
			WO 2002-SE228	W	20020208

IT **90357-06-5**, Bicalutamide
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release multiparticulate solid dispersion formulation containing amphiphilic lipid matrix)
RN 90357-06-5 CAPLUS
CN Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



AB The present invention is directed to a multiparticulate, modified release solid dispersion formulation, comprising a drug substance having a water-solubility of ≤ 8 mg/mL at room temperature, a hydrophobic matrix former which is a water insol., non-swelling amphiphilic lipid, and a hydrophilic matrix former which is a meltable, water-soluble excipient. The weight ratio of hydrophobic matrix former to hydrophilic matrix former is ≥ 1, and the **particle** size is < 300 μm. Also a unit dosage of the same, as well as process for the preparation thereof and the use of the formulation and unit dosage are claimed. For example, felodipine (1 g) was dissolved in a melt of 4 g cetanol at 110° and 2 g of Poloxamer 407 was added into the melt. The melted mixture was kept at 110° and atomized at air temperature of 400° and a pressure of 7 bar; the **particles** were collected into a vessel which was kept at temperature -50°, and thereafter dried over night in a vacuum oven at 25° and 2 mbar. The resulted **particles** had a 90% fractile size (90% smaller than) of 77 μm and a roundness of 0.87.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:293419 CAPLUS
DOCUMENT NUMBER: 136:315004
TITLE: Liposomes encapsulating anticancer drugs and the use thereof in the treatment of malignant tumors
INVENTOR(S): Parente Duena, Antonio; Pons Lambiez, Ferran; Fabra Fres, Angels; Polo Trasancos, Maria Dolores; Garces

Garces, Josep; Reig Isart, Francesca
PATENT ASSIGNEE(S): Lipotec, S.A., Spain
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030397	A1	20020418	WO 2001-ES367	20011003
WO 2002030397	C2	20040513		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2186484	A1	20030501	ES 2000-2447	20001010
ES 2186484	B1	20040701		
AU 2001091904	A5	20020422	AU 2001-91904	20011003
EP 1325739	A1	20030709	EP 2001-972111	20011003
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013552	A	20030729	BR 2001-13552	20011003
JP 2004510811	T2	20040408	JP 2002-533840	20011003

PRIORITY APPLN. INFO.: ES 2000-2447 A 20001010
WO 2001-ES367 W 20011003

IT **90357-06-5**, Bicalutamide
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(lipopeptide liposomes encapsulating anticancer drugs and the use thereof in the treatment of malignant tumors)

RN 90357-06-5 CAPLUS

CN Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



AB The invention relates to liposomes encapsulating anticancer drugs and the use thereof in the treatment of malignant tumors. The liposomes are covered by a lipopeptide consisting of three substructures: a lipid fragment, an active oligopeptide and a spacer oligopeptide between the two fragments. Said liposomes can be used in i.v. administration for the treatment of malignant tumors.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   34.16      39.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -3.50      -3.50

STN INTERNATIONAL LOGOFF AT 18:20:54 ON 20 OCT 2004
```